<DOC>
	<DOC>NCT03093701</DOC>
	<brief_summary>Subjects with macular edema will be screened and eligible subject will be enrolled to receive a single dose of the study drug (TLC399) with either of the three dose strengths by intravitreal (IVT) route. Each of the three groups will include approximately 22 subjects. The subjects will be followed for visual acuity, safety, tolerability and retinal thickness assessment after the single IVT injection of the study drug on Day 1.</brief_summary>
	<brief_title>TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>Be male or female, at least 18 years of age. Have macular edema due to CRVO or BRVO Have a bestcorrected visual acuity (BCVA) score of 20/40 to 20/400 Have a mean central subfield thickness (CST) â‰¥350 um Be willing and able to comply with the study procedure and sign a written informed consent. Must agree to use a medically acceptable form of birth control Poorly controlled diabetes History of significant intraocular pressure (IOP) elevation to steroid treatment History of ocular hypertension and glaucoma Cataract surgery in the study eye within 3 months, or intraocular surgery within 6 months prior to the Screening Visit Use of hemodilution for the treatment of RVO Use of IVT ranibizumab or bevacizumab in the study eye within 6 weeks prior to the Screening Visit; or IVT aflibercept within 8 weeks prior to the Screening Visit. IVT Ozurdex to the study eye within 6 months prior to the Screening Visit. Prior use of Retisert or Iluvien Use of systemic steroids or heparin within 1 month prior to the Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>